Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial.
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
LKB1/STRAD promotes axon initiation during neuronal polarization.
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.
Barcelona Pediatric MS and Related Disorders Update Meeting
Testicular hypofunction and multiple sclerosis risk: a record-linkage study.
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Product Portfolio, Meda
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of masitinib in the treatment of pancreatic cancer
Nephrotic-range proteinuria on interferon-β treatment: immune-induced glomerulonephritis or other pathway?
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Current and future immunotherapy targets in autoimmune neurology.
Ampyra (dalfampridine)
Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma.
Iran mass produces MS drug Ziferon
Posturography in MS patients treated with high dose methylprednisolone.

Pages